Company intelligence / Profile preview

DyDo Pharma

Osaka, Osaka Prefecture, Japandydopharma.co.jp ↗

Ownership: Private
Development stage: Other

Overview

DyDo Pharma focuses on developing and commercializing therapies for rare and ultra-rare diseases, with a particular emphasis on pediatric conditions. Its lead program, Firdapse® (amifampridine phosphate), has been approved in Japan for the treatment of muscle weakness in Lambert-Eaton myasthenic syndrome. The company accelerates development by licensing drug candidates from global bioventures to obtain marketing authorization approvals in Japan as quickly as possible[1][2].

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Licensing partnerships with global bioventures to bring orphan drugs to the Japanese market; specific partners are undisclosed but business model centers around alliances and collaborations

Beyond the preview

Go deeper on DyDo Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DyDo Pharma.

Explore the full profile